Overview Dividends

(KYMR) Kymera Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5015751044

IRAK4, STAT6, TYK2, Protein Degradation

KYMR EPS (Earnings per Share)

EPS Growth (3Y CAGR): -44.11%
EPS Trend (3Y Correlation): -51.6%

KYMR Revenue

Revenue Growth (3Y CAGR): -47.36%
Revenue Trend (3Y Correlation): -30.4%

Risk via 10d forecast
Volatility	50.5%
Value at Risk 5%th	98.6%
Relative Tail Risk	-9.92%

Reward TTM
Sharpe Ratio	0.68
Alpha	9.52

Character TTM
Hurst Exponent	0.506
Beta	1.659
Beta Downside	1.350

Drawdowns 3y
Max DD	71.69%
Mean DD	23.49%
Median DD	19.23%

Description: KYMR Kymera Therapeutics November 08, 2025

Kymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biotech that designs small-molecule degraders-often called PROTACs-to harness the body’s ubiquitin-proteasome system and eliminate disease-causing proteins.

The company’s lead pipeline centers on an IRAK4 inhibitor currently in a Phase II trial for hidradenitis suppurativa and atopic dermatitis, with a second STAT6-targeted candidate for type 2 inflammatory disorders and a TYK2 program aimed at broader autoimmune indications.

Kymera has a strategic alliance with Sanofi that provides an upfront payment of roughly $50 million and up to $300 million in milestone potential for non-oncology IRAK4 programs, giving the firm a non-dilutive cash infusion and validation of its degrader platform.

As of the latest 10-Q, Kymera reported cash and equivalents of about $200 million, supporting roughly 18 months of runway at its current burn rate of $70 million per year; the biotech sector’s R&D spend is growing at a 9 % CAGR, while the global targeted protein degradation market is projected to expand at ~14 % CAGR through 2030, underscoring a favorable macro backdrop for Kymera’s technology.

For a deeper quantitative view, the ValueRay platform offers a granular breakdown of KYMR’s valuation metrics and comparable peer analysis.

KYMR Stock Overview

Market Cap in USD	4,578m
Sub-Industry	Biotechnology
IPO / Inception	2020-08-21
Return 12m vs S&P 500	32.4%
Analyst Rating	4.55 of 5

KYMR Dividends

Currently no dividends paid

KYMR Growth Ratios

CAGR 3y	31.40%
CAGR/Max DD Calmar Ratio	0.44
CAGR/Mean DD Pain Ratio	1.34
Current Volume	1146.2k
Average Volume	698.4k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-295.1m TTM) > 0 and > 6% of Revenue (6% = 2.62m TTM)

FCFTA -0.21 (>2.0%) and ΔFCFTA -6.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 1044 % (prev 573.5%; Δ 470.8pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.21 (>3.0%) and CFO -227.9m > Net Income -295.1m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 7.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (87.3m) change vs 12m ago 14.68% (target <= -2.0% for YES)

Gross Margin -83.38% (prev 92.85%; Δ -176.2pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 4.09% (prev 8.46%; Δ -4.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -875.0 (EBITDA TTM -285.9m / Interest Expense TTM 337.0k) >= 6 (WARN >= 3)

Altman Z'' -8.62

(A) 0.41 = (Total Current Assets 528.3m - Total Current Liabilities 71.6m) / Total Assets 1.10b

(B) -0.89 = Retained Earnings (Balance) -979.0m / Total Assets 1.10b

(D) -6.27 = Book Value of Equity -977.5m / Total Liabilities 155.8m

Total Rating: -8.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 27.36

1. Piotroski 0.0pt = -5.0

2. FCF Yield -5.54% = -2.77

3. FCF Margin data missing

4. Debt/Equity 0.09 = 2.50

5. Debt/Ebitda 0.10 = 2.49

6. ROIC - WACC (= -38.24)% = -12.50

7. RoE -33.35% = -2.50

8. Rev. Trend -30.44% = -2.28

9. EPS Trend -51.55% = -2.58

What is the price of KYMR shares?

As of November 17, 2025, the stock is trading at USD 64.94 with a total of 1,146,189 shares traded.
Over the past week, the price has changed by +6.01%, over one month by +7.41%, over three months by +48.88% and over the past year by +53.12%.

Is Kymera Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Kymera Therapeutics (NASDAQ:KYMR) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 27.36 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KYMR is around 57.14 USD . This means that KYMR is currently overvalued and has a potential downside of -12.01%.

Is KYMR a buy, sell or hold?

Kymera Therapeutics has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy KYMR.

Strong Buy: 14
Buy: 3
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the KYMR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	74.6	14.8%
Analysts Target Price	74.6	14.8%
ValueRay Target Price	65.7	1.1%

KYMR Fundamental Data Overview November 15, 2025

Market Cap USD = 4.58b (4.58b USD * 1.0 USD.USD)
P/S = 104.6786
P/B = 4.832
Beta = 2.296
Revenue TTM = 43.7m USD
EBIT TTM = -294.9m USD
EBITDA TTM = -285.9m USD
Long Term Debt = 84.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 84.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -29.0m USD (from netDebt column, last quarter)
Enterprise Value = 4.16b USD (4.58b + Debt 84.0m - CCE 505.7m)
Interest Coverage Ratio = -875.0 (Ebit TTM -294.9m / Interest Expense TTM 337.0k)
FCF Yield = -5.54% (FCF TTM -230.2m / Enterprise Value 4.16b)
FCF Margin = -526.4% (FCF TTM -230.2m / Revenue TTM 43.7m)
Net Margin = -674.8% (Net Income TTM -295.1m / Revenue TTM 43.7m)
Gross Margin = -83.38% ((Revenue TTM 43.7m - Cost of Revenue TTM 80.2m) / Revenue TTM)
Gross Margin QoQ = -2581 % (prev 81.84%)
Tobins Q-Ratio = 3.77 (Enterprise Value 4.16b / Total Assets 1.10b)
Interest Expense / Debt = 0.12% (Interest Expense 98.0k / Debt 84.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -233.0m (EBIT -294.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.38 (Total Current Assets 528.3m / Total Current Liabilities 71.6m)
Debt / Equity = 0.09 (Debt 84.0m / totalStockholderEquity, last quarter 946.3m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -29.0m / EBITDA -285.9m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -29.0m / FCF TTM -230.2m)
Total Stockholder Equity = 884.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.78% (Net Income -295.1m / Total Assets 1.10b)
RoE = -33.35% (Net Income TTM -295.1m / Total Stockholder Equity 884.9m)
RoCE = -30.43% (EBIT -294.9m / Capital Employed (Equity 884.9m + L.T.Debt 84.0m))
RoIC = -26.33% (negative operating profit) (NOPAT -233.0m / Invested Capital 884.9m)
WACC = 11.91% (E(4.58b)/V(4.66b) * Re(12.13%) + D(84.0m)/V(4.66b) * Rd(0.12%) * (1-Tc(0.21)))
Discount Rate = 12.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.14%
Fair Price DCF = unknown (Cash Flow -230.2m)
EPS Correlation: -51.55 | EPS CAGR: -44.11% | SUE: -0.55 | # QB: 0
Revenue Correlation: -30.44 | Revenue CAGR: -47.36% | SUE: -1.95 | # QB: 0

Additional Sources for KYMR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle